These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38957203)

  • 1. Mobile addiction treatment and harm reduction services as tools to address health inequities: a community case study of the Brockton Neighborhood Health Center mobile unit.
    Pinkhover A; Celata K; Baker T; Chatterjee A; Lunze K
    Front Public Health; 2024; 12():1407522. PubMed ID: 38957203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions.
    Chatterjee A; Baker T; Rudorf M; Walt G; Stotz C; Martin A; Kinnard EN; McAlearney AS; Bosak J; Medley B; Pinkhover A; Taylor JL; Samet JH; Lunze K
    J Subst Use Addict Treat; 2024 Apr; 159():209272. PubMed ID: 38128649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mobile addiction service for community-based overdose prevention.
    Pepin MD; Joseph JK; Chapman BP; McAuliffe C; O'Donnell LK; Marano RL; Carreiro SP; Garcia EJ; Silk H; Babu KM
    Front Public Health; 2023; 11():1154813. PubMed ID: 37538275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
    Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
    [No Abstract]   [Full Text] [Related]  

  • 6. Collaborative approach to harm reduction by managed care pharmacy team for populations with substance use disorder.
    Osibanjo O; Reinhardt R; Clemans S; Andoniadis S; Carson P; Benkstein K
    J Am Pharm Assoc (2003); 2023; 63(1):396-402. PubMed ID: 36564331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HEALing (Helping to End Addiction Long-term
    HEALing Communities Study Consortium
    Drug Alcohol Depend; 2020 Dec; 217():108335. PubMed ID: 33248391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets.
    Hsu M; Jung OS; Kwan LT; Jegede O; Martin B; Malhotra A; Suzuki J
    J Subst Use Addict Treat; 2024 Feb; 157():209216. PubMed ID: 37981243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for the implementation of a statewide mobile addiction program.
    Tschampl CA; Regis C; Johnson NE; Davis MT; Hodgkin D; Brolin MF; Do E; Horgan CM; Green TC; Reilly B; Duska M; Taveras EM
    J Comp Eff Res; 2023 May; 12(5):e220117. PubMed ID: 36988165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago.
    Messmer SE; Elmes AT; Jimenez AD; Murphy AL; Guzman M; Watson DP; Poorman E; Mayer S; Infante AF; Keller EG; Whitfield K; Jarrett JB
    J Subst Use Addict Treat; 2023 Jul; 150():209054. PubMed ID: 37088399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons Learned from Implementation of a Post-opioid Overdose Outreach Program in a Rural Massachusetts Community.
    Senthilkumar R; Bailey A; Moner E; Parduhn T; Evans EA
    Community Ment Health J; 2024 Apr; 60(3):482-493. PubMed ID: 37902945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community selected strategies to reduce opioid-related overdose deaths in the HEALing (Helping to End Addiction Long-term
    Chandler R; Nunes EV; Tan S; Freeman PR; Walley AY; Lofwall M; Oga E; Glasgow L; Brown JL; Fanucchi L; Beers D; Hunt T; Bowers-Sword R; Roeber C; Baker T; Winhusen TJ
    Drug Alcohol Depend; 2023 Apr; 245():109804. PubMed ID: 36780768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for community-driven selection of strategies to implement evidence-based practices to reduce opioid overdoses in the HEALing Communities Study: a trial to evaluate a community-engaged intervention in Kentucky, Massachusetts, New York and Ohio.
    Young AM; Brown JL; Hunt T; Sprague Martinez LS; Chandler R; Oga E; Winhusen TJ; Baker T; Battaglia T; Bowers-Sword R; Button A; Fallin-Bennett A; Fanucchi L; Freeman P; Glasgow LM; Gulley J; Kendell C; Lofwall M; Lyons MS; Quinn M; Rapkin BD; Surratt HL; Walsh SL
    BMJ Open; 2022 Sep; 12(9):e059328. PubMed ID: 36123106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LatinX harm reduction capital, medication for opioid use disorder, and nonfatal overdose: A structural equation model analysis among people who use drugs in Massachusetts.
    Shrestha S; Stopka TJ; Hughto JMW; Case P; Palacios WR; Reilly B; Green TC
    Drug Alcohol Depend; 2024 Jun; 259():111293. PubMed ID: 38643530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community Care in Reach: Mobilizing Harm Reduction and Addiction Treatment Services for Vulnerable Populations.
    Regis C; Gaeta JM; Mackin S; Baggett TP; Quinlan J; Taveras EM
    Front Public Health; 2020; 8():501. PubMed ID: 33102413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adapting inpatient addiction medicine consult services during the COVID-19 pandemic.
    Harris MTH; Peterkin A; Bach P; Englander H; Lapidus E; Rolley T; Weimer MB; Weinstein ZM
    Addict Sci Clin Pract; 2021 Feb; 16(1):13. PubMed ID: 33627183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.